Cowen Downgrades Alimera Sciences (ALIM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq advance as soft inflation tempers Fed rate-hike bets
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
Alimera Sciences Announces First Quarter 2016 Financial Results
May 4, 2016 4:23 PM EDTFirst quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN® sales in the U.S.Record benefit investigations in the first quarter indicate increasing physician demandOver 5,000 eyes treated with ILUVIEN® in four primary marketsAlimera to host conference call on May 5, 2016 at 10:00 AM ET
ATLANTA, May 04, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of... More
